Medical Treatments for Prostate CancerThere are many different medical treatments for prostate cancer that involve the clinical care of a healthcare professional. These treatments include expectant therapy, surgery, radiation therapy, hormone therapy, and chemotherapy. Expectant therapy is to carefully observe and monitor the prostate cancer. Because prostate cancer cells often spread very slowly, many older men who have the disease may not need more extensive treatment. However, expectant therapy usually includes routine physician examinations, including digital rectal exams and PSA tests. The different types of surgery for prostate cancer are radical prostatectomy - an open-surgery procedure in which the entire prostate gland and surrounding tissue are removed. Transurethral resection of the prostate (TURP) - surgery to remove part of the prostate gland that surrounds the urethra. Cryosurgery - this procedure involves killing the cancer cells by freezing them with a small metal tool placed in the tumor. Side effects of prostate cancer surgery include incontinence and impotence. Incontinence is the inability to control urine and may result in dribbling of urine, especially immediately after surgery. Normal control usually returns within weeks or months after surgery. Impotence is the inability to achieve an erection. For a month, or so, after surgery, most men are not able to get an erection. Eventually, approximately 40 to 60 percent of men will be able to get an erection sufficient for sexual intercourse, but without ejaculation of semen, since removal of the prostate gland prevents that process.Radiation therapy uses high energy rays to kill or shrink cancer cells, and to decrease their ability to divide. Radiation is often used to treat prostate cancer that is still confined to the prostate gland, or has spread only to nearby tissue. If the disease is advanced, radiation may be used to reduce the size of the tumor and to provide relief from symptoms. Possible side effects of radiation for prostate cancer may include diarrhea, with or without blood in the stool, and colitis, problems associated with urination, a degree of impotence (inability to get an erection), which may occur within two years of radiation therapy. The goal of hormone therapy is to lower the level of male hormones in the body, particularly testosterone. Hormone therapy does not cure the cancer, and is often used to treat persons whose cancer has spread or recurred after treatment. Produced mainly in the testicles, testosterone causes prostate cancer cells to grow. Thus, reduced testosterone levels can make the prostate cancer shrink and become less active. Most studies show that hormone therapy works better if it is started early. Chemotherapy is the use of powerful, anti-cancer medications to kill cancer cells.. Hospitalization may be needed to monitor treatment and chemotherapy's side effects. Common side effects of chemotherapy include: nausea and vomiting, hair loss, anemia, reduced ability of blood to clot, mouth sores, increased likelihood of developing infections, fatigue. Most side effects disappear once treatment is stopped. |
| docetaxel prostate |
|
Medical News: ASCO PROSTATE: Docetaxel-Based Therapy Viewed for 26 -- Docetaxel (Taxotere)-based combination therapy using is being investigated in a dozen trials for hormone refractory prostate cancer, Precautions and Warnings With Docetaxel - Prostate Cancer Follow Articles: Precautions and Warnings With Docetaxel - Prostate Cancer Follow-up Care. IngentaConnect Docetaxel: In Hormone-Refractory Metastatic The taxoid analogue docetaxel is a potent inhibitor of microtubular depolymerisation and, in hormone-refractory metastatic prostate cancer, it also counters IngentaConnect Docetaxel (Taxotere) in the treatment of prostate Docetaxel (Taxotere^) is a taxoid derived from the needles of the European yew tree, Taxus baccata. With an overall prostate-specific antigen response rate CRD: Docetaxel in combination with prednisone or prednisolone for A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer. Drug Insight: use of docetaxel in prostate and urothelial cancers The main focus of this review is on the data from phase II and phase III trials examining the use of docetaxel in men with hormone-refractory prostate The Lancet Oncology : Docetaxel for prostate cancer - Published by Patients with androgen-independent prostate cancer randomly assigned to docetaxel progress later than those randomly assigned to vinorelbine (J Urol 2007; sanofi-aventis : European Union Approval for Taxotere^ (docetaxel European Union Approval for Taxotere^ (docetaxel) in Prostate Cancer. Aventis, part of the sanofi-aventis Group announced today that the European Commission Prostate cancer (hormone-refractory) - docetaxel Docetaxel is recommended as a possible treatment for men with hormone-refractory metastatic prostate cancer. It should be given only if the man is well Prostate cancer (hormone-refractory) - docetaxel Prostate cancer (hormone-refractory) - docetaxel. Docetaxel for the treatment of hormone refractory prostate cancer. Status:, History Docetaxel and Prostate Cancer Chemotherapy Docetaxel is chemotherapy drug classified with the taxane group and used in the treatment of advanced prostate cancer and recurrent prostate cancer. Chemo Extends Life in Advanced Prostate Cancer - National Cancer Chemotherapy regimens that include the drug docetaxel extend median survival by two to three months in patients with advanced prostate cancer that is no EU Approval for Taxotere(R) (docetaxel) in Prostate Cancer The European Commission has approved Taxotere(R) (docetaxel) Injection Concentrate for use in combination with prednisone as a treatment for men with Phase II study of weekly docetaxel in symptomatic androgen Background This study sought to define the activity and toxicity of weekly docetaxel in patients with androgen-independent prostate cancer and Docetaxel (Taxotere) in hormone-refractory prostate cancer. If the promise of docetaxel hormone-refractory prostate cancer is realized, it may be appropriate to design clinical trials that evaluate docetaxel-based NEJM -- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone Docetaxel Followed by Castration Improves Outcomes in LNCaP Prostate . The Activity of Docetaxel in Early Prostate Cancer or the Successful Collaboration The Prostate Cancer Charity - News Story We welcome NICE guidance, issued today, that recommends all eligible prostate cancer patients have access to the prostate cancer drug docetaxel (Taxotere). Men with advanced, incurable prostate cancer can benefit from Men with advanced prostate cancer can benefit from Taxotere (docetaxel) chemotherapy. Increases life expectancy, reduces pain, and improves quality of life DOCETAXEL EXTENDS LIFE IN ADVANCED PROSTATE CANCER PATIENTS Two months may not sound like much time to most people, but the study shows that prostate cancer responds to docetaxel and this opens up the door to explore |
| docetaxel prostate |
|
cancer progression prostate chili peppers prostate cancer2c prostate2c hormone therapy american prostate cancer foundation |